Cosmos Health Inc.: Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders'
Cosmos Health reported Q2 2026 revenue of $19.0M, up 29% YoY, with adjusted gross profit increasing 58%. Total liabilities decreased 13%, and stockholders' equity rose 12%. The company's share repurchase program is active, with 5.1M shares repurchased so far. Revenue growth was driven by all core segments, including Decahedron, Cana Laboratories, and CosmoFarm.
How this was made
The 30-second read
Why it matters
The earnings beat and share repurchase signal operational momentum, but ongoing losses and modest cash reserves suggest caution.
Market read
First‑report earnings release for a micro‑cap health‑care company; provides fresh data for short‑term traders.
What to watch
Liquidity is thin with only $4.15M of liquid assets; any slowdown in contract orders could pressure the stock.
Background
Cosmos Health is a vertically integrated health‑care group listed on NASDAQ, focusing on nutraceuticals, contract manufacturing, and pharmacy distribution.
Ticker impact
Cosmos Health reported Q2 2026 results with record revenue, adjusted gross profit up 58% and a new $5M share repurchase program.
Potential modest upside of 5‑8% over the next week as investors digest earnings and buyback news.
Revenue beat expectations, margin expansion, and a fresh buyback tranche provide clear catalysts for buying pressure.
Market effects
Highlights growth in the nutraceutical and contract manufacturing segments, potentially lifting peers in health‑care services.
Positive for U.S. health‑care stocks; limited impact outside North America.
Modest, confined to small‑cap health‑care niche.
Counterpoint
Despite revenue growth, the company remains loss‑making; cash burn and reliance on buybacks could limit upside.
Key entities
- CompanyCosmos Health Inc.
NASDAQ‑listed health‑care firm reporting Q2 2026 results.
